Charles River Laboratories International, Inc.
CRL · New York Stock Exchange · USD
353,34USD
+15,82 (+4,69 %)Stand 9. Nov., 21:00
Vorbörslich359,30+5,96 (+1,69 %)7:46 ET
Kennzahlen
- Eröffnung
- 344,32
- Vortag
- 337,52
- Tagesspanne
- 342,00 – 358,77
- 52 Wochen
- 146,20 – 379,63
- Volumen
- 943.084
- Ø Volumen
- 1,01 Mio.
- Börsenwert
- 16,93 Mrd. $
- KGV
- 346,4
- Gewinn je Aktie (TTM)
- 0,91
- Dividendenrendite
- 0,0 %
- Beta
- 1,3
- Nächste Zahlen
- 17. Feb. 2027
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 4,02 Mrd. | 4,05 Mrd. | 4,13 Mrd. | 3,98 Mrd. | 3,54 Mrd. |
| Herstellungskosten | 2,79 Mrd. | 2,72 Mrd. | 2,63 Mrd. | 2,51 Mrd. | 2,21 Mrd. |
| Bruttogewinn | 1,23 Mrd. | 1,33 Mrd. | 1,5 Mrd. | 1,46 Mrd. | 1,33 Mrd. |
| Forschung und Entwicklung | 0 | 0 | 0 | 0 | 0 |
| Vertrieb und Verwaltung | 743,07 Mio. | 751 Mio. | 747,86 Mio. | 665,1 Mio. | 619,92 Mio. |
| Operatives Ergebnis | 507,84 Mio. | 227,35 Mio. | 617,26 Mio. | 650,98 Mio. | 589,86 Mio. |
| EBITDA | 410,84 Mio. | 581,14 Mio. | 1,03 Mrd. | 986,15 Mio. | 820,16 Mio. |
| Nettogewinn | −144,34 Mio. | 10,3 Mio. | 474,62 Mio. | 486,23 Mio. | 390,98 Mio. |
| Gewinn je Aktie (verwässert) | -2,91 | 0,20 | 9,22 | 9,48 | 7,60 |
Umsatz nach Segment
Produkte · FY 2025
- Discovery and Safety Assessment2,4 Mrd. $59,84 %−1,97 %
- Research Models and Services846,08 Mio. $21,07 %+2,01 %
- Manufacturing Support766,41 Mio. $19,09 %−0,38 %
Anteil · ggü. Vorjahr (FY 2024)
Regionen · FY 2025
- UNITED STATES2,14 Mrd. $54,22 %−4,38 %
- Europe1,1 Mrd. $27,91 %+2,28 %
- CANADA501,03 Mio. $12,68 %+3,93 %
- Asia Pacific205,02 Mio. $5,19 %+4,10 %
Anteil · ggü. Vorjahr (FY 2024)
Bewertung
Letzte 12 Monate
- KGV
- 346,4
- Kurs-Umsatz-Verhältnis
- 4,3
- Kurs-Buchwert-Verhältnis
- 5,2
- PEG
- -3,9
- Bruttomarge
- 32,9 %
- Operative Marge
- 14,1 %
- Nettomarge
- 1,0 %
- Verschuldungsgrad
- 0,9
- EV/EBITDA
- 66,8
- Eigenkapitalrendite
- 1,3 %
- Kapitalrendite (ROIC)
- −3,8 %
- Free-Cashflow-Rendite
- 2,4 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 30,5 % | 32,9 % | 36,4 % | 36,8 % | 37,7 % |
| Operative Marge | 12,6 % | 5,6 % | 14,9 % | 16,4 % | 16,7 % |
| Nettomarge | −3,6 % | 0,3 % | 11,5 % | 12,2 % | 11,0 % |
| KGV | -70,0 | 930,8 | 25,5 | 22,8 | 47,5 |
| Kurs-Umsatz-Verhältnis | 2,5 | 2,4 | 2,9 | 2,8 | 5,2 |
| Kurs-Buchwert-Verhältnis | 3,2 | 2,8 | 3,4 | 3,7 | 7,3 |
| Verschuldungsgrad | 1,0 | 0,8 | 0,9 | 1,0 | 1,3 |
| Liquidität 3. Grades | 1,3 | 1,4 | 1,5 | 1,3 | 1,2 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 12,95 Mrd. | 12,09 Mrd. | 14,9 Mrd. | 13,94 Mrd. | 21,53 Mrd. |
| EV/EBITDA | 31,5 | 20,8 | 14,4 | 14,1 | 26,2 |
| Eigenkapitalrendite | −4,6 % | 0,3 % | 13,2 % | 16,3 % | 15,4 % |
| Kapitalrendite (ROIC) | 8,4 % | 0,9 % | 7,1 % | 7,9 % | 8,1 % |
| Free-Cashflow-Rendite | 5,1 % | 5,2 % | 3,0 % | 2,7 % | 2,9 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | −0,9 % | −1,9 % | +3,9 % | +12,3 % | +21,1 % |
| Bruttogewinn | −8,0 % | −11,4 % | +2,7 % | +9,6 % | +24,3 % |
| Operatives Ergebnis | +123,4 % | −63,2 % | −5,2 % | +10,4 % | +36,3 % |
| Nettogewinn | −1.501,7 % | −97,8 % | −2,4 % | +24,4 % | +7,3 % |
| Gewinn je Aktie | −1.555,0 % | −97,8 % | −2,7 % | +24,7 % | +5,6 % |
| Freier Cashflow | +3,4 % | +37,3 % | +23,9 % | −44,6 % | +40,0 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen · Buy
- 1Stark kaufen
- 27Kaufen
- 9Halten
- 0Verkaufen
- 0Stark verkaufen
Kursziel
308,36
Durchschnitt · −12,73 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 3,94 Mrd. | 4,04 Mrd. | 4,27 Mrd. |
| Umsatz (Tief – Hoch) | 3,92 Mrd. – 3,97 Mrd. | 3,96 Mrd. – 4,1 Mrd. | 4,09 Mrd. – 4,33 Mrd. |
| Gewinn je Aktie (Ø) | 11,45 | 12,89 | 14,37 |
| Gewinn je Aktie (Tief – Hoch) | 11,24 – 11,60 | 12,19 – 13,16 | 10,60 – 18,59 |
| Analysten | 9 | 10 | 5 |
Letzte Änderungen
- Barclays5. Nov. 2026Overweight
- RBC Capital5. Nov. 2026Outperform
- UBS5. Nov. 2026Buy
- Evercore ISI Group5. Nov. 2026Outperform
- Morgan Stanley13. Okt. 2026Overweight
- Jefferies28. Sept. 2026Buy
- TD Cowen25. Sept. 2026Buy
- Deutsche Bank25. Sept. 2026Buy
Quartalszahlen
Nächste Zahlen: 17. Feb. 2027| Nov. 2026 | Aug. 2026 | Mai 2026 | Feb. 2026 | Nov. 2025 | Aug. 2025 | Mai 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 2,97 | 2,74 | 1,96 | 2,33 | 2,32 | 2,50 | 2,06 | 2,50 |
| Gewinn je Aktie · Tatsächlich | 3,09 | 3,02 | 2,06 | 2,39 | 2,43 | 3,12 | 2,34 | 2,66 |
| Abweichung | +4,04 % | +10,22 % | +5,10 % | +2,58 % | +4,74 % | +24,80 % | +13,59 % | +6,40 % |
| Umsatz · Tatsächlich | 982,73 Mio. | 1 Mrd. | 995,83 Mio. | 994,23 Mio. | 1 Mrd. | 1,03 Mrd. | 984,17 Mio. | 1 Mrd. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
–
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 118,20 %
- Investoren mit 13F-Meldung
- 585
Größte Investoren
- FMR LLC8,74 %4,24 Mio.
- BLACKROCK, INC.7,83 %3,8 Mio.
- VANGUARD CAPITAL MANAGEMENT LLC6,50 %3,15 Mio.
- INVESCO LTD.6,16 %2,98 Mio.
- HARRIS ASSOCIATES L P4,62 %2,24 Mio.
- VANGUARD PORTFOLIO MANAGEMENT LLC4,56 %2,21 Mio.
- ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC3,93 %1,91 Mio.
- STATE STREET CORP3,81 %1,86 Mio.
Insider-Geschäfte
- Knell Michael Gunnar6. Nov. 2026 · officer: SVP, Finance and CAOVerkauf649 Aktien · 313,02
- FOSTER JAMES C22. Okt. 2026 · directorKauf24.042 Aktien · 244,41
- FOSTER JAMES C22. Okt. 2026 · directorVerkauf24.042 Aktien · 350,00
- FOSTER JAMES C22. Okt. 2026 · directorVerkauf24.042 Aktien · 244,41
- Parisotto Shannon M21. Okt. 2026 · officer: CEVP, Disc & Safety AssessmentKauf2156 Aktien · 244,41
- Parisotto Shannon M21. Okt. 2026 · officer: CEVP, Disc & Safety AssessmentVerkauf2156 Aktien · 344,41
- Parisotto Shannon M21. Okt. 2026 · officer: CEVP, Disc & Safety AssessmentVerkauf2156 Aktien · 244,41
- Parisotto Shannon M5. Okt. 2026 · officer: CEVP, Disc & Safety AssessmentKauf981 Aktien · 208,44
Vergleichbare Unternehmen
2268.HKWuXi XDC Cayman Inc73,15+2,38 %
300759.SZPharmaron Beijing Co., Ltd.45,19+1,55 %
603127.SSJoinn Laboratories(China)Co.,Ltd.46,18−0,86 %
CERTCertara, Inc.12,22+1,41 %
GNNSFGenscript Biotech Corporation3,95−12,22 %
HNGZYHangzhou Tigermed Consulting Co., Ltd4,450,00 %
ICLRICON Public Limited Company207,59+1,39 %
MEDPMedpace Holdings, Inc.672,93+3,03 %
Über das Unternehmen
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Führung
- Birgit GirshickCEO & Director
- Joseph W. LaPlumeCorporate Executive Vice President of Corporate Development & Strategy
- Victoria L. CreamerCorporate Executive Vice President & Chief People Officer
- Glenn G. ColemanCorporate Executive Vice President & Chief Financial Officer
- Michael Gunnar KnellCorporate Senior Vice President & Chief Accounting Officer
- Brian F. BathgateCorporate Senior Vice President of European Safety Assessment
- CEO
- Birgit Girshick
- Mitarbeitende
- 19.000
- Hauptsitz
- Wilmington, MA, US
- Sektor
- Healthcare
- Branche
- Medical - Diagnostics & Research
- Börsengang
- 23. Juni 2000
- Website
- criver.com
Nachrichten
- PRNewsWire · 10. Nov., 3:55Tigermed to Participate in the Privatization of Frontage Holdings Corporation and Divest Its Overseas Laboratory Services Business
- Zacks Investment Research · 9. Nov., 10:51Here's Why Charles River Laboratories (CRL) is a Strong Momentum Stock
- Zacks Investment Research · 9. Nov., 10:16Unlocking Charles River (CRL) International Revenues: Trends, Surprises, and Prospects
- Business Wire · 9. Nov., 6:10Charles River Laboratories to Acquire Frontage's Bioanalysis and DMPK Businesses
- MarketBeat · 5. Nov., 8:17Charles River Laboratories International Q3 Earnings Call Highlights
- Defense World · 5. Nov., 4:00Boston Trust Walden Corp Sells 37,537 Shares of Charles River Laboratories International, Inc. $CRL
- Seeking Alpha · 4. Nov., 14:14Charles River Laboratories International, Inc. (CRL) Q3 2026 Earnings Call Transcript
- Zacks Investment Research · 4. Nov., 11:06Charles River Q3 Earnings & Revenues Top Estimates, Stock Rises
- Zacks Investment Research · 4. Nov., 10:31Charles River (CRL) Reports Q3 Earnings: What Key Metrics Have to Say
- Zacks Investment Research · 4. Nov., 9:11Charles River Laboratories (CRL) Tops Q3 Earnings and Revenue Estimates
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.